That’s in USD I believe. In AUD, capturing just 10% of total anthracycline market would be around $200 per share. And assuming first-in-class and best-in-class CPACS validation, 10% market share sounds fairly conservative in my opinion…
To paraphrase Dr T, do we really think based on available information that Race has less than 1% chance of succeeding? Personally, I think it’s much higher.
Cardioprotection thread, page-472
-
- There are more pages in this discussion • 416 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
-0.030(2.10%) |
Mkt cap ! $238.5M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.46 | $1.38 | $123.1K | 87.00K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 19987 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 330 | 1 |
View Market Depth
| Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |